Raptor Technology (RAPT) Prices 2.5M Common Stock Offering at $30/Share

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its underwritten public offering of 2,500,000 shares of common stock at a public offering price of $30.00 per share.

In addition, the underwriters have been granted a 30-day option to purchase up to an additional 375,000 shares of common stock at the public offering price, less the underwriting discount. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by RAPT, are expected to be $75.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on February 11, 2020, subject to the satisfaction of customary closing conditions.

BMO Capital Markets, Wells Fargo Securities, UBS Investment Bank and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering.

You May Also Be Interested In

• Pershing Square Selling About 80.6m Shares In Universal Music - Bloomberg
• SpaceX files for 555.56M share IPO at $135/sh
• Gossamer Bio reports 90.5% participation in convertible note exchange